Three-quarters of pharmacies expect surge in demand for weight-loss pill
UK pharmacies are preparing for a surge in demand for the newly approved oral weight-loss pill, Wegovy. While the drug offers a non-injectable alternative for patients, pharmacists have expressed significant concerns regarding the rise of unregulated black-market sales.
Why it matters
The accessibility of weight-loss medications highlights the tension between public health demand and the risks posed by unregulated online pharmaceutical markets.
More than three-quarters (76%) of pharmacies expect to start “significant numbers” of eligible patients on oral Wegovy (semaglutide; Novo Nordisk) , a survey by the National Pharmacy Association (NPA) has found.
The article presents data from a survey and quotes industry representatives without taking a stance on the medication itself.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in